A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-08-25. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerdiseaseevidence ofmonthsmetastases
  Phrases that lowered it: combinationefficacy andand safetyrefrain fromevaluate the
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past termination rate: 9.9% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 112 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 23.5% (raises risk) · Drug's FDA history
• Sponsor's past trials: 1181 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 173790 (lowers risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Drug's FAERS reports marked serious: 94.2% (raises risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Keywords listed: 0 (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase Ⅱ Clinical Trial NCT07719738 · started 2026 · scored riskier than 38% of active trials completed
• NGS as the First-line Treatment in Advanced Biliary Tract Cancer NCT04172402 · started 2019 · scored riskier than 54% of active trials completed
• Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC NCT04066491 · started 2019 · scored riskier than 88% of active trials terminated
• A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC NCT01267344 · started 2010 · scored riskier than 74% of active trials completed
• BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer NCT01679405 · started 2012 · scored riskier than 62% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.